keyword
MENU ▼
Read by QxMD icon Read
search

Valsartan

keyword
https://www.readbyqxmd.com/read/28529582/angiotensin-ii-receptor-blockers-induce-autophagy-in-prostate-cancer-cells
#1
Yunseo Woo, Yu-Jin Jung
Angiotensin II receptor blockers (ARBs) are anti-hypertensive drugs that competitively inhibit the binding of angiotensin II to its receptor, resulting in blood vessel dilation and the reduction of blood pressure. These antagonists are also known as sartans, and are a group of pharmaceuticals that possess tetrazole or imidazole groups. In the present study, the anticancer and antimetastatic effects of the ARBs fimasartan, losartan, eprosartan and valsartan on the human prostate cancer PC-3, DU-145 and LNCap-LN3 cell lines were investigated in vitro...
May 2017: Oncology Letters
https://www.readbyqxmd.com/read/28527109/erratum-to-clinical-pharmacokinetics-of-sacubitril-valsartan-lcz696-a-novel-angiotensin-receptor-neprilysin-inhibitor
#2
Surya Ayalasomayajula, Thomas Langenickel, Parasar Pal, Sreedevi Boggarapu, Gangadhar Sunkara
Sacubitril/valsartan (LCZ696) is indicated for the treatment of heart failure with reduced ejection fraction. Absorption of sacubitril/valsartan and conversion of sacubitril (prodrug) to sacubitrilat (neprilysin inhibitor) was rapid with maximum plasma concentrations of sacubitril, sacubitrilat, and valsartan (angiotensin receptor blocker) reaching within 0.5, 1.5-2.0, and 2.0-3.0 h, respectively. With a twofold increase in dose, an increase in the area under the plasma concentration-time curve was proportional for sacubitril, ~1...
May 19, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28520449/-novelties-in-the-treatment-of-heart-failure
#3
Filip Souček, Jan Novak
Heart failure (HF) is a complex clinical syndrome which is manifested by characteristic symptoms and objective signs of cardiac insufficiency. The incidence of HF, particularly its chronic form, is estimated 0.4-2 % in the central and western Europe, with an increase in higher age groups, affecting 10-20 % of the population aged over 80. With respect to its growing incidence and prevalence, novel modalities of pharmacological and non-pharmacological treatment are being developed in order to improve quality of life and survival of the affected patients...
2017: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/28514719/multiway-analysis-methods-applied-to-the-fluorescence-excitation-emission-dataset-for-the-simultaneous-quantification-of-valsartan-and-amlodipine-in-tablets
#4
Erdal Dinç, Zehra Ceren Ertekin, Eda Büker
In this study, excitation-emission matrix datasets, which have strong overlapping bands, were processed by using four different chemometric calibration algorithms consisting of parallel factor analysis, Tucker3, three-way partial least squares and unfolded partial least squares for the simultaneous quantitative estimation of valsartan and amlodipine besylate in tablets. In analyses, preliminary separation step was not used before the application of parallel factor analysis Tucker3, three-way partial least squares and unfolded partial least squares approaches for the analysis of the related drug substances in samples...
April 30, 2017: Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy
https://www.readbyqxmd.com/read/28509722/rationale-for-nebivolol-valsartan-combination-for-hypertension-review-of-preclinical-and-clinical-data
#5
Thomas D Giles, John R Cockcroft, Bertram Pitt, Abhijeet Jakate, Harold M Wright
: To treat hypertension, combining two or more antihypertensive drugs from different classes is often necessary. β-Blockers and renin-angiotensin-aldosterone system inhibitors, when combined, have been deemed 'less effective' based on partially overlapping mechanisms of action and limited evidence. Recently, the single-pill combination (SPC) of nebivolol (Neb) 5 mg - a vasodilatory β1-selective antagonist/β3 agonist - and valsartan 80 mg, an angiotensin II receptor blocker, was US Food and Drug Administration-approved for hypertension...
May 15, 2017: Journal of Hypertension
https://www.readbyqxmd.com/read/28507434/enhanced-oral-bioavailability-of-valsartan-using-a-polymer-based-supersaturable-self-microemulsifying-drug-delivery-system
#6
Dong Woo Yeom, Bo Ram Chae, Ho Yong Son, Jin Han Kim, Jun Soo Chae, Seh Hyon Song, Dongho Oh, Young Wook Choi
A novel, supersaturable self-microemulsifying drug delivery system (S-SMEDDS) was successfully formulated to enhance the dissolution and oral absorption of valsartan (VST), a poorly water-soluble drug, while reducing the total quantity for administration. Poloxamer 407 is a selectable, supersaturating agent for VST-containing SMEDDS composed of 10% Capmul(®) MCM, 45% Tween(®) 20, and 45% Transcutol(®) P. The amounts of SMEDDS and Poloxamer 407 were chosen as formulation variables for a 3-level factorial design...
2017: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/28493020/development-and-validation-of-an-analytical-method-based-on-liquid-chromatography-tandem-mass-spectrometry-detection-for-the-simultaneous-determination-of-13-relevant-wastewater-derived-contaminants-in-lettuce
#7
Nicola Montemurro, Cristina Postigo, Antonio Lonigro, Sandra Perez, Damià Barceló
We present an analytical method developed and validated to study the potential uptake of 13 selected drugs (ten pharmaceuticals, one illicit drug, and two transformation products) into lettuce plants from contaminated water and soil. Some of the selected drugs (i.e., cocaine, methadone, cis-diltiazem, valsartan, and valsartan acid), which are commonly present in treated wastewater, were investigated for the first time in plant tissues. The method is based on ultrasonic solvent extraction with acetonitrile-methanol (1:1, v/v) and subsequent automated extract cleanup and analysis by means of online solid-phase extraction-liquid chromatography-tandem mass spectrometry...
May 11, 2017: Analytical and Bioanalytical Chemistry
https://www.readbyqxmd.com/read/28492561/-sacubitril-valsartan-a-new-and-effective-treatment-for-heart-failure-with-reduced-ejection-fraction
#8
Michele Senni, Bruno Trimarco, Michele Emdin, Luciano De Biase
Despite significant therapeutic advances, patients with chronic heart failure and reduced ejection fraction (HFrEF) remain at high risk for heart failure progression and death. The PARADIGM-HF study, the largest outcome trial in HFrEF, has shown improved cardiovascular outcomes with sacubitril/valsartan (Entresto®, Novartis), previously known as LCZ696, compared with angiotensin-converting enzyme (ACE) inhibitor therapy, possibly leading us to a new era for heart failure treatment. Sacubitril/valsartan represents a first-in-class drug acting through inhibition of angiotensin receptor and neprilysin, thus modulating the renin-angiotensin-aldosterone system and vasoactive substances such as natriuretic peptides...
January 2017: Giornale Italiano di Cardiologia
https://www.readbyqxmd.com/read/28490725/effects-of-valsartan-and-amlodipine-on-oxidative-stress-in-type-2-diabetic-patients-with-hypertension-a-randomized-multicenter-study
#9
Hae Jin Kim, Seung Jin Han, Dae Jung Kim, Hak Chul Jang, Soo Lim, Sung Hee Choi, Yong Hyun Kim, Dong Hyun Shin, Se Hwa Kim, Tae Ho Kim, Yu Bae Ahn, Seung Hyun Ko, Nan Hee Kim, Ji A Seo, Ha Young Kim, Kwan Woo Lee
BACKGROUND/AIMS: Oxidative stress plays an important role in the pathogenesis and progression of diabetic complications and antagonists of renin-angiotensin system and amlodipine have been reported previously to reduce oxidative stress. In this study, we compared the changes in oxidative stress markers after valsartan and amlodipine treatment in type 2 diabetic patients with hypertension and compared the changes in metabolic parameters. METHODS: Type 2 diabetic subjects with hypertension 30 to 80 years of age who were not taking antihypertensive drugs were randomized into either valsartan (n = 33) or amlodipine (n = 35) groups and treated for 24 weeks...
May 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/28489317/pharmacogenomics-of-angiotensin-receptor-neprilysin-inhibitor-and-its-long-term-side-effects
#10
REVIEW
Chayakrit Krittanawong, Takeshi Kitai
The development of the promising agent sacubitril/valsartan, known as an angiotensin receptor blocker-neprilysin inhibitor (ARNI), to improve heart failure (HF) management, may benefit morbidity, mortality, and readmission rates in patients with HF. The PARADIGM-HF trial demonstrated that the ARNI can reduce morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF), while ongoing PARAMOUNT and PARAGON-HF trials determined whether the ARNI has morbidity and mortality benefits in patients with heart failure with preserved ejection fraction (HFpEF)...
May 10, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28473934/in-acute-iga-nephropathy-proteinuria-and-creatinine-are-in-the-spot-but-podocyturia-operates-in-silence-any-place-for-amiloride
#11
H Trimarchi, M Paulero, R Canzonieri, A Schiel, A Iotti, C Costales-Collaguazo, A Stern, M Forrester, F Lombi, V Pomeranz, R Iriarte, T Rengel, I Gonzalez-Hoyos, A Muryan, E Zotta
IgA nephropathy is the most frequent cause of primary glomerulonephritis, portends erratic patterns of clinical presentation, and lacks specific treatment. In general, it slowly progresses to end-stage renal disease. The clinical course and the response to therapy are usually assessed with proteinuria and serum creatinine. Validated biomarkers have not been identified yet. In this report, we present a case of acute renal injury with proteinuria and microscopic hematuria in a young male. A kidney biopsy disclosed IgA nephropathy...
2017: Case Reports in Nephrology
https://www.readbyqxmd.com/read/28473234/structural-description-of-the-marketed-form-of-valsartan-a-crystalline-mesophase-characterized-by-nanocrystals-and-conformational-disorder
#12
Yannick Guinet, Laurent Paccou, Florence Danède, Patrick Derollez, Alain Hédoux
Valsartan is an antihypertensive drug, recognized to be marketed in an amorphous state, different from that obtained by quenching the liquid state below Tg. This is an unusual and very original situation, given that the amorphous state is unstable. Low-wavenumber Raman spectroscopy and X-ray diffraction investigations were carried out on the various solid-state forms of valsartan. It was found that the marketed form is not amorphous and can be described in terms of mesophase in which the long-range order of the stable crystal is limited on the lengthscale of tens nanometers, inducing a melting temperature lower than that of the stable crystalline state, inherent to the crystallite size...
May 1, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28465251/danshen-injection-prevents-heart-failure-by-attenuating-post-infarct-remodeling
#13
Lingyan Wang, Jiahui Yu, Patrick Asare Fordjour, Xiaoxue Xing, Hui Gao, Yanyan Li, Lingyan Li, Yan Zhu, Xiumei Gao, Guanwei Fan
ETHNOPHARMACOLOGICAL RELEVANCE: Danshen Injection (DSI) is a traditional Chinese medicine extracted from Danshen, prepared from the dried root and rhizome of Salvia miltiorrhiza Bunge. Danshen is an ancient antipyretic traditional Chinese medicine which is mostly used to improve blood circulation and dispel blood stasis. Danshen decoction or liquor-fried Danshen (with grain-based liquor) which is cool in nature is traditionally used to 'cool the blood' and reduce the swelling of sores and abscesses...
April 29, 2017: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/28460381/sacubitril-valsartan-in-heart-failure
#14
Kevin E Vitting
No abstract text is available yet for this article.
May 2, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28460380/sacubitril-valsartan-in-heart-failure
#15
Bennett E Werner
No abstract text is available yet for this article.
May 2, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28460379/sacubitril-valsartan-in-heart-failure
#16
Brad Spellberg
No abstract text is available yet for this article.
May 2, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28460378/sacubitril-valsartan-in-heart-failure
#17
Milton Packer, W Mark Armstrong, Joseph M Rothstein, Michael Emmett
No abstract text is available yet for this article.
May 2, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28454835/noncardiovascular-deaths-are-more-common-than-cardiovascular-deaths-in-patients-with-cardiovascular-disease-or-cardiovascular-risk-factors-and-impaired-glucose-tolerance-insights-from-the-nateglinide-and-valsartan-in-impaired-glucose-tolerance-outcomes-research
#18
Abhinav Sharma, Flávio de Souza Brito, Jie-Lena Sun, Laine Thomas, Steven Haffner, Rury R Holman, Renato D Lopes
BACKGROUND: Patients with impaired glucose tolerance have an elevated risk of cardiovascular (CV) death; however, the causes and risk factors associated with non-CV deaths are poorly understood. METHODS: The NAVIGATOR trial enrolled 9,306 participants with impaired glucose tolerance and CV disease or at high CV risk, with a median follow-up of 6.4years. Using this population, we identified (1) the proportion of deaths attributed to CV, non-CV, and unknown causes, and (2) the risk factors associated with non-CV death...
April 2017: American Heart Journal
https://www.readbyqxmd.com/read/28454798/the-design-of-the-valsartan-for-attenuating-disease-evolution-in-early-sarcomeric-hypertrophic-cardiomyopathy-vanish-trial
#19
Carolyn Y Ho, John J V McMurray, Allison L Cirino, Steven D Colan, Sharlene M Day, Akshay S Desai, Steven E Lipshultz, Calum A MacRae, Ling Shi, Scott D Solomon, E John Orav, Eugene Braunwald
Hypertrophic cardiomyopathy (HCM) is often caused by sarcomere gene mutations, resulting in left ventricular hypertrophy (LVH), myocardial fibrosis, and increased risk of sudden cardiac death and heart failure. Studies in mouse models of sarcomeric HCM demonstrated that early treatment with an angiotensin receptor blocker (ARB) reduced development of LVH and fibrosis. In contrast, prior human studies using ARBs for HCM have targeted heterogeneous adult cohorts with well-established disease. The VANISH trial is testing the safety and feasibility of disease-modifying therapy with an ARB in genotyped HCM patients with early disease...
May 2017: American Heart Journal
https://www.readbyqxmd.com/read/28452844/life-threatening-angioedema-due-to-valsartan-sacubitril-with-previously-well-tolerated-ace-inhibitor
#20
Hitesh Raheja, Vivek Kumar, Stephan Kamholz, Gerald Hollander, Jacob Shani
No abstract text is available yet for this article.
April 25, 2017: American Journal of Therapeutics
keyword
keyword
16092
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"